Evidence map›Paper›PMID 35610229›Full record

ArticleScientific reports2022

Development of a stable antibody production system utilizing an Hspa5 promoter in CHO cells.

Hiroki Tanemura, Kenji Masuda, Takeshi Okumura, Eri Takagi, Daisuke Kajihara, Hirofumi Kakihara, Koichi Nonaka, Ryo Ushioda

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hiroki TanemuraBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Kenji MasudaBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Takeshi OkumuraBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Eri TakagiBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Daisuke KajiharaBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Hirofumi KakiharaBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Koichi NonakaBiologics Technology Research Laboratories Biologics Division, Daiichi Sankyo Co., Ltd., 2716-1, Aza Kurakake, Oaza Akaiwa, Chiyoda-machi, Oura-gun, Gunma, 370-0503, Japan.
Ryo UshiodaFaculty of Life Sciences, Kyoto Sangyo University, Motoyama, Kamigamo, Kita-ku, Kyoto City, 603-8555, Japan. ryo3ussy3@cc.kyoto-su.ac.jp.
Daiichi-Sankyo (Japan) · JPKyoto Sangyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese hamster ovary (CHO) cells are widely used for manufacturing antibody drugs. We attempted to clone a novel high-expression promoter for producing monoclonal antibodies (mAbs) based on transcriptome analysis to enhance the transcriptional abundance of mAb genes. The efficacy of conventional promoters such as CMV and hEF1α decrease in the latter phase of fed-batch cell culture. To overcome this, we screened genes whose expression was maintained or increased throughout the culture period. Since CHO cells have diverse genetic expression depending on the selected clone and culture medium, transcriptome analysis was performed on multiple clones and culture media anticipated to be used in mAb manufacturing. We thus acquired the Hspa5 promoter as a novel high-expression promoter, which uniquely enables mAb productivity per cell to improve late in the culture period. Productivity also improved for various IgG subclasses under Hspa5 promoter control, indicating this promoter's potential universal value for mAb production. Finally, it was suggested that mAb production with this promoter is correlated with the transcription levels of endoplasmic reticulum stress-related genes. Therefore, mAb production utilizing the Hspa5 promoter might be a new method for maintaining protein homeostasis and achieving stable expression of introduced mAb genes during fed-batch culture.

Indexed as

Antibody FormationBatch Cell Culture TechniquesAnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusCulture MediaAntibodies, MonoclonalCulture Media

Identifiers

PMID35610229
PMCPMC9130236
OpenAlexW4281398324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.